BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25917051)

  • 1. Oral Lichen Planus in IBD Patients: A Paradoxical Adverse Effect of Anti-TNF-α Therapy.
    Andrade P; Lopes S; Albuquerque A; Osório F; Pardal J; Macedo G
    Dig Dis Sci; 2015 Sep; 60(9):2746-9. PubMed ID: 25917051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus.
    Worsnop F; Wee J; Natkunarajah J; Moosa Y; Marsden R
    Clin Exp Dermatol; 2012 Dec; 37(8):879-81. PubMed ID: 22548502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
    Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
    J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
    Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
    J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
    Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists.
    Asarch A; Gottlieb AB; Lee J; Masterpol KS; Scheinman PL; Stadecker MJ; Massarotti EM; Bush ML
    J Am Acad Dermatol; 2009 Jul; 61(1):104-11. PubMed ID: 19539844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
    Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy.
    Iriarte A; Zaera C; Bachiller-Corral J; López-Sanromán A
    Gastroenterol Hepatol; 2017 Feb; 40(2):117-121. PubMed ID: 26993096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary levels of tumor necrosis factor-alpha in oral lichen planus.
    Pezelj-Ribaric S; Prso IB; Abram M; Glazar I; Brumini G; Simunovic-Soskic M
    Mediators Inflamm; 2004 Apr; 13(2):131-3. PubMed ID: 15203556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
    Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
    Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-α, TNF-β and IL-10 gene polymorphism and association with oral lichen planus risk in Saudi patients.
    Al-Mohaya MA; Al-Harthi F; Arfin M; Al-Asmari A
    J Appl Oral Sci; 2015; 23(3):295-301. PubMed ID: 26221924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Kim JW; Shim JJ; Jang JY
    J Korean Med Sci; 2015 Feb; 30(2):173-9. PubMed ID: 25653489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
    Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.
    Dulai PS; Siegel CA; Peyrin-Biroulet L
    Gastroenterol Clin North Am; 2014 Sep; 43(3):441-56. PubMed ID: 25110252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.